Capricor Therapeutics, Inc.
CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.93
Price-5.57%
-$0.35
1Y
Price
Market Cap
$271.102m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$13.393m
-39.9%
1y CAGR+278.5%
3y CAGR+444.3%
5y CAGREarnings
-$69.977m
-72.9%
1y CAGR-43.8%
3y CAGR-44.0%
5y CAGREPS
-$1.64
-42.6%
1y CAGR-17.2%
3y CAGR-21.8%
5y CAGRBook Value
$104.977m
$133.569m
Assets$28.592m
Liabilities$4.420m
DebtDebt to Assets
3.3%
-0.1x
Debt to EBITDAFree Cash Flow
-$47.176m
-13.6%
1y CAGR-646.5%
3y CAGR-457.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company